2014’s Top Biopharma Dealmakers

Related Deals

• Geron grants Janssen Biotech global rights to imetelstat; deal terminated
• Aduro, Janssen sign second agreement this year, this time for lung cancer; deal terminated
• Janssen gets rights to Vertex's influenza A candidates
• Pfizer to build its immuno-oncology pipeline through tie-up with Merck KGAA
• Pfizer pays $635mm for Baxter's two marketed vaccines
• Pfizer adds to rare disease pipeline with worldwide rights to Opko's growth hormone
• Alnylam, Genzyme expand their RNAi therapies alliance, Genzyme invests $700mm; deal restructured
• Sanofi gets exclusive global rights to MannKind's newly approved Afrezza diabetes treatment; later terminated
• Novartis gets nonexclusive rights to use Oxford’s LentiVector in oncology
• On the heels of FDA approval, Anacor partners Kerydin with Sandoz’s PharmaDerm
• BioLineRx finds first Big Pharma collaborator in Novartis, which takes equity stake
• NewLink partners immune checkpoint inhibitor NLG919 with Genentech; rights returned; terminated
• Roche signs epigenetics collaboration with Oryzon Genomics; terminated
• Roche targets multi-drug resistant Gram-negative bacteria in Discuva deal; extended
• Actavis becomes white knight for Allergan; buys firm for $65bn
• Dublin-based generics company Actavis buys US spec pharma Forest Laboratories for $23.9bn
• Novartis acquires GSK’s cancer drug assets for $14.5bn up front
• Merck sells OTC operations to Bayer for $14.2bn
• Merck pays $102 per share for Cubist
• Roche acquires InterMune for $8bn
• Glaxo pays $5.25bn up front for Novartis’ vaccines business
• LabCorp acquires CRO Covance for $6.1bn
• Mylan pays $5.6bn for Abbott's developed markets branded generics pharmaceuticals business
• Mallinckrodt pays $5.3bn in cash and stock for spec pharma Questcor